Adalimumab Biosimilar ADA2403(Oddifact)

阿达木单抗 ADA2403(Oddifact)

Report date: 2025/07/31 16:04:46

Base Information

Drug NameAdalimumab Biosimilar ADA2403(Oddifact)
Drug Alias NameADA-2403
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsRheumatic Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFrance
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesOddifact SAS
China Registration ClassN/A

Develop Information

Active CompaniesOddifact SAS
Inactive CompaniesN/A
Active IndicationsRheumatic Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A